Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) ROE % : 0.00% (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Clarus Therapeutics Holdings's annualized net income for the quarter that ended in Jun. 2022 was $-42.78 Mil. Clarus Therapeutics Holdings's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $-21.71 Mil. Therefore, Clarus Therapeutics Holdings's annualized ROE % for the quarter that ended in Jun. 2022 was N/A%.

The historical rank and industry rank for Clarus Therapeutics Holdings's ROE % or its related term are showing as below:

CRXTQ's ROE % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 4.15
* Ranked among companies with meaningful ROE % only.

Clarus Therapeutics Holdings ROE % Historical Data

The historical data trend for Clarus Therapeutics Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings ROE % Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

ROE %

Negative Equity

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
ROE %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Clarus Therapeutics Holdings's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's ROE % falls into.

Clarus Therapeutics Holdings ROE % Calculation

Clarus Therapeutics Holdings's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %	=	Net Income (A: Dec. 2021 )	/	( (Total Stockholders Equity (A: Dec. 2020 )	+	Total Stockholders Equity (A: Dec. 2021 ))	/ count )
	=	-40.617	/	( (-325.78	+	-15.919)	/ 2 )
	=	-40.617	/	-170.8495
	=	N/A %

Clarus Therapeutics Holdings's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %	=	Net Income (Q: Jun. 2022 )	/	( (Total Stockholders Equity (Q: Mar. 2022 )	+	Total Stockholders Equity (Q: Jun. 2022 ))	/ count )
	=	-42.776	/	( (-30.357	+	-13.063)	/ 2 )
	=	-42.776	/	-21.71
	=	N/A %

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2022) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Clarus Therapeutics Holdings (OTCPK:CRXTQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

	ROE %		(Q: Jun. 2022 )
=	Net Income	/	Total Stockholders Equity
=	-42.776	/	-21.71
=	(Net Income / Revenue )	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-42.776 / 16.2)	*	(16.2 / 42.731)	*	(42.731 / -21.71)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-264.05 %	*	0.3791	*	N/A
=	ROA %	*	Equity Multiplier
=	-100.1 %	*	N/A
=	N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

	ROE %		(Q: Jun. 2022 )
=	Net Income	/	Total Stockholders Equity
=	-42.776	/	-21.71
=	(Net Income / Pre-Tax Income)	*	(Pre-Tax Income / Operating Income)	*	(Operating Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-42.776 / -42.776)	*	(-42.776 / -42.608)	*	(-42.608 / 16.2)	*	(16.2 / 42.731)	*	(42.731 / -21.71)
=	Tax Burden	*	Interest Burden	*	Operating Margin %	*	Asset Turnover	*	Equity Multiplier
=	1	*	1.0039	*	-263.01 %	*	0.3791	*	N/A
=	N/A %

Note: The net income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
^* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Clarus Therapeutics Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » ROE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402